{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:50:38Z","timestamp":1784749838069,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.hfc.2024.03.001","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T13:24:41Z","timestamp":1712237081000},"page":"283-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Use of Biomarkers in Cardiac Amyloidosis"],"prefix":"10.1016","volume":"20","author":[{"given":"Andrea","family":"Lalario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Saro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2024.03.001_bib1","doi-asserted-by":"crossref","first-page":"1026440","DOI":"10.3389\/fcvm.2022.1026440","article-title":"Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies","volume":"9","author":"Porcari","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.hfc.2024.03.001_bib2","doi-asserted-by":"crossref","first-page":"749523","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination","volume":"8","author":"Porcari","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.001_bib3","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.hfc.2024.03.001_bib4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2020.03.007","article-title":"Utility of Biomarkers in Cardiac Amyloidosis","volume":"8","author":"Pregenzer-Wenzler","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"16","key":"10.1016\/j.hfc.2024.03.001_bib5","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hfc.2024.03.001_bib6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.hfc.2024.03.001_bib7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/aps.2018.38","article-title":"Current and future circulating biomarkers for cardiac amyloidosis","volume":"39","author":"Luciani","year":"2018","journal-title":"Acta Pharmacol Sin"},{"issue":"45","key":"10.1016\/j.hfc.2024.03.001_bib8","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","article-title":"Restrictive cardiomyopathy: definition and diagnosis","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.hfc.2024.03.001_bib9","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.001_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.001_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.hfc.2024.03.001_bib12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"(Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.hfc.2024.03.001_bib13","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2024.03.001_bib14","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.001_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10741-022-10247-5","article-title":"Endomyocardial biopsy in the clinical context: current indications and challenging scenarios","volume":"28","author":"Porcari","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.001_bib16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaccao.2021.05.004","article-title":"Two Decades of Cardiac Amyloidosis: A Danish Nationwide Study","volume":"3","author":"Westin","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.001_bib17","doi-asserted-by":"crossref","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis\u2013associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"19","key":"10.1016\/j.hfc.2024.03.001_bib18","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","article-title":"Biomarkers of cardiovascular disease: molecular basis and practical considerations","volume":"113","author":"Vasan","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2024.03.001_bib19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.106.683110","article-title":"Benchmarks for the assessment of novel cardiovascular biomarkers","volume":"115","author":"Morrow","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.001_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"20","key":"10.1016\/j.hfc.2024.03.001_bib21","doi-asserted-by":"crossref","first-page":"10916","DOI":"10.3390\/ijms222010916","article-title":"Biomarkers in AL amyloidosis","volume":"22","author":"Fotiou","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.hfc.2024.03.001_bib22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.001_bib23","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/s41598-017-15424-3","article-title":"Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells","volume":"7","author":"Imperlini","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.hfc.2024.03.001_bib24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2459\/JCM.0000000000000349","article-title":"Different NT-proBNP circulating levels for different types of cardiac amyloidosis","volume":"17","author":"Perfetto","year":"2016","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.001_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.hfc.2024.03.001_bib26","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J"},{"issue":"Suppl 1","key":"10.1016\/j.hfc.2024.03.001_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/13506129.2011.574354033","article-title":"Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients","volume":"18","author":"Russo","year":"2011","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.hfc.2024.03.001_bib28","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.001_bib29","first-page":"e518","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"\u00c5","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.001_bib30","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis","volume":"96","author":"Ticau","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.001_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","article-title":"Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy","volume":"27","author":"Maia","year":"2020","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.001_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","article-title":"Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis","volume":"28","author":"Louwsma","year":"2021","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.001_bib33","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s11739-022-02958-2","article-title":"Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist","volume":"17","author":"Perfetto","year":"2022","journal-title":"Intern Emerg Med"},{"issue":"24","key":"10.1016\/j.hfc.2024.03.001_bib34","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2024.03.001_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.001_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/10408363.2019.1670133","article-title":"Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory","volume":"57","author":"Caponi","year":"2020","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.001_bib37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.hfc.2024.03.001_bib38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hfc.2024.03.001_bib39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hfc.2024.03.001_bib40","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/bcj.2015.34","article-title":"Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death","volume":"5","author":"Warsame","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.001_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.hfc.2024.03.001_bib42","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/biomedicines10081906","article-title":"The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism","volume":"10","author":"Sanguinetti","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.001_bib43","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","article-title":"Genetic Stabilization of Transthyretin, Cerebrovascular Disease, and Life Expectancy","volume":"33","author":"Hornstrup","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.001_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/13506129.2010.483118","article-title":"Serum transthyretin levels in Swedish TTR V30M carriers","volume":"17","author":"Buxbaum","year":"2010","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.001_bib45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/13506120802525285","article-title":"Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity","volume":"15","author":"Buxbaum","year":"2008","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.001_bib46","doi-asserted-by":"crossref","first-page":"e004000","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10.1016\/j.hfc.2024.03.001_bib47","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cardfail.2021.05.009","article-title":"Retinol Binding Protein 4 as a Screening Biomarker for Hereditary TTR Amyloidosis in African American Adults With TTR V142I","volume":"27","author":"Kontorovich","year":"2021","journal-title":"J\u00a0Card Fail"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.001_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"9371","key":"10.1016\/j.hfc.2024.03.001_bib49","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.hfc.2024.03.001_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hfc.2024.03.001_bib51","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"30","key":"10.1016\/j.hfc.2024.03.001_bib52","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis\u2019: Is it already on the verge of obsolescence?","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"27","key":"10.1016\/j.hfc.2024.03.001_bib53","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.001_bib54","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/ehf2.13847","article-title":"A\u00a0simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan","volume":"9","author":"Nakashima","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.001_bib55","doi-asserted-by":"crossref","first-page":"e0173086","DOI":"10.1371\/journal.pone.0173086","article-title":"Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"12","author":"Kristen","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.001_bib56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ejhf.2016","article-title":"Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis","volume":"23","author":"Nicol","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.001_bib57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.001_bib58","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00392-019-01559-y","article-title":"A\u00a0novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis","volume":"109","author":"Kreusser","year":"2020","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.001_bib59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jcmg.2022.07.008","article-title":"Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis","volume":"16","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.hfc.2024.03.001_bib60","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.001_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/10428190701684518","article-title":"Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. in light-chain amyloidosis","volume":"49","author":"Gertz","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.001_bib62","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"36","key":"10.1016\/j.hfc.2024.03.001_bib63","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hfc.2024.03.001_bib64","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2024.03.001_bib65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","article-title":"Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery","volume":"82","author":"Porcari","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.001_bib66","first-page":"424","article-title":"I\u00a0dieci punti che il cardiologo deve conoscere su scintigrafia miocardica con traccianti ossei, amiloidosi e cuore [Ten questions for the cardiologist about cardiac scintigraphy with bone tracers, amyloidosis and the heart]","volume":"23","author":"Porcari","year":"2022","journal-title":"G\u00a0Ital Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.001_bib67","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1093\/eurjpc\/zwac237","article-title":"Comparison of different technetium-99m-labelled bone tracers for imaging cardiac amyloidosis","volume":"30","author":"Porcari","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hfc.2024.03.001_bib68","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","article-title":"Myocardial Amyloidosis: The Exemplar Interstitial Disease","volume":"12","author":"Fontana","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"45","key":"10.1016\/j.hfc.2024.03.001_bib69","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:26:00Z","timestamp":1717590360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713624000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1551713624000175"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2024.03.001","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Use of Biomarkers in Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2024.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}